Handelsavisen
prelaunch
Companies Healthcare SHUR.BO
SH
SHUR.BO BSE (India) Pharmaceuticals

Shukra Pharmaceuticals Ltd

$31,40
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
0,03 %
Op margin
29,8 %
ROE
15,2 %
Net margin
29,4 %
Debt / equity
0,07
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Shukra Pharmaceuticals Ltd is a pharmaceutical company that generates revenue primarily through the development, manufacturing, and sale of prescription drugs and healthcare products.

Business. Shukra Pharmaceuticals Ltd (SHUR.BO) is a pharmaceutical company engaged in the research, development, and sale of healthcare products. The firm operates within the broader pharmaceuticals and medical research industry, generating revenue primarily through product sales. Headquartered in India, the company is listed on the Bombay Stock Exchange. Specific details regarding operating segments or geographic revenue breakdowns are not disclosed in the available data.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
15,2 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning SHUR.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to SHUR.BO. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Shukra Pharmaceuticals Ltd (SHUR.BO) is a pharmaceutical company engaged in the research, development, and sale of healthcare products. The firm operates within the broader pharmaceuticals and medical research industry, generating revenue primarily through product sales. Headquartered in India, the company is listed on the Bombay Stock Exchange. Specific details regarding operating segments or geographic revenue breakdowns are not disclosed in the available data.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    Shukra Pharmaceuticals Ltd maintains a strong liquidity position, with a current ratio of 3.79, indicating the company can cover its short-term liabilities more than three times over. The company's liquidity_fpt score suggests it has sufficient operating cash flow to meet its obligations, though it is not in a position of high liquidity. The company's free cash flow of INR 54.58 million supports its operational flexibility and capacity for reinvestment.

    In terms of profitability, Shukra Pharmaceuticals Ltd demonstrates a return on equity (ROE) of 15.24% and a return on assets (ROA) of 11.04%, both of which are strong indicators of efficient capital use and asset management. These figures suggest the company is performing well relative to its equity and asset base, though a direct comparison to industry medians is not available in the current dataset. The company's operating margin, derived from its operating income of INR 97.25 million on revenue of INR 325.87 million, is also robust, indicating effective cost control and pricing power.

    The company's revenue is concentrated in a single business segment, as disclosed in its financials, with no geographic breakdown provided in the available data. This lack of diversification may expose the company to higher risk if demand in its primary market fluctuates. However, the absence of geographic segmentation also means the company is not overly reliant on any one region, which could be a mitigating factor.

    Looking ahead, the company's revenue is expected to grow in the current fiscal year, though the exact percentage is not disclosed in the available data. The company's capital expenditure of INR -27.43 million suggests it is not currently investing heavily in new infrastructure or expansion, which may indicate a focus on maintaining existing operations rather than aggressive growth. This could be a strategic decision to preserve cash or a sign of limited growth opportunities in the near term.

    The risk assessment for Shukra Pharmaceuticals Ltd indicates a medium liquidity risk and a low dilution risk. The company's debt-to-equity ratio of 0.07 is low, suggesting it is not heavily leveraged and has a strong equity base. However, the note that net cash is negative after subtracting total debt implies the company may have some short-term liquidity constraints. The dilution risk is low, and no significant dilution events are expected in the near term, as the number of shares outstanding has not changed between basic and diluted figures.

    Recent events, including filings and transcripts, are not detailed in the available data, so no specific recent developments can be cited. The company's financials suggest a stable and profitable operation, but without additional disclosures, it is difficult to assess the impact of external factors such as regulatory changes or competitive pressures.

    Key takeaways
    • Shukra Pharmaceuticals Ltd has a strong liquidity position with a current ratio of 3.79, indicating it can easily cover its short-term liabilities.
    • The company's ROE of 15.24% and ROA of 11.04% suggest efficient use of equity and assets, though industry comparisons are not available.
    • Revenue is concentrated in a single business segment, with no geographic diversification disclosed, which may increase exposure to market-specific risks.
    • The company is not currently investing heavily in capital expenditures, which may indicate a conservative approach to growth or limited expansion opportunities.
    • The company has a low debt-to-equity ratio of 0.07 and a low dilution risk, suggesting a strong equity base and limited pressure from share dilution.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $31,40
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $628.4M
    Net cash
    -$41.8M
    Current ratio
    3.8
    Debt / equity
    0.1
    ROA
    11.0%
    ROE
    15.2%
    Cash conversion
    83.0%
    CapEx / revenue
    -8.4%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin29,8 %Best in class
    Net Margin29,4 %Best in class
    ROE15,2 %Above P75
    Capex / Rev-8,4 %Below median
    D/E0,07Above median
    Cash Conv0,83Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • Shukra Pharmaceuticals Ltd Market data — financials · 2026-05-29

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    SHUR.BOCanonical
    BSE (India) · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage